Genelux (Genelux) Operating Cash Flow per Share : $-0.76 (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Genelux Operating Cash Flow per Share?

Genelux's operating cash flow per share for the three months ended in Mar. 2024 was $-0.16. Genelux's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.76.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -39.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Genelux's Operating Cash Flow per Share or its related term are showing as below:

GNLX' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -39.6 Med: -39.6 Max: -39.6
Current: -39.6

During the past 4 years, Genelux's highest 3-Year average Operating Cash Flow per Share Growth Rate was -39.60% per year. The lowest was -39.60% per year. And the median was -39.60% per year.

GNLX's 3-Year OCF Growth Rate is ranked worse than
85.4% of 1233 companies
in the Biotechnology industry
Industry Median: 3.5 vs GNLX: -39.60

Genelux Operating Cash Flow per Share Historical Data

The historical data trend for Genelux's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genelux Operating Cash Flow per Share Chart

Genelux Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

-0.31

-0.28

-0.15

-0.83

Genelux Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Operating Cash Flow per Share	Get a 7-Day Free Trial									-0.23	-0.22	-0.13	-0.26	-0.16

Competitive Comparison of Genelux's Operating Cash Flow per Share

For the Biotechnology subindustry, Genelux's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genelux's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genelux's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Genelux's Price-to-Operating-Cash-Flow falls into.

Genelux Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Genelux's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-20.275	/	24.429
	=	-0.83

Genelux's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )	=	Cash Flow from Operations (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	-4.354	/	26.850
	=	-0.16

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.76

Genelux Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Genelux's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Genelux (Genelux) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genelux Corp (NAS:GNLX) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

2625 Townsgate Road, Suite 230, Westlake Village, CA, USA, 91361

Website

https://www.genelux.com

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

Executives

Tony Yu	officer: VP, Clinical Trial Operations	C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
James L Tyree	director	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
John Thomas	director	C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Aladar Szalay	10 percent owner	C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Sean Ryder	officer: General Counsel	C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
John W Smither	director	C/O KYTHERA BIOPHARMACEUTICALS, INC., 27200 WEST AGOURA ROAD, SUITE 200, CALABASAS CA 91301
Lourie S. Zak	officer: Chief Financial Officer	C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Thomas Zindrick	director, officer: President and CEO	C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE. 230, WESTLAKE VILLAGE CA 91361
Joseph Cappello	officer: VP, Pharmaceutical Development	C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Doug Samuelson	officer: Chief Financial Officer	C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Caroline Jewett	officer: Head of Quality	C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Ralph Smalling	officer: Head of Regulatory	C/O GENELUX CORPORATION, 2625 TOWNSGATE RD., STE 230, WESTLAKE VILLAGE CA 91361
Qian Zhang	officer: Associate VP, Research	C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Mary Mirabelli	director	C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361
Paul Scigalla	officer: Chief Medical Officer	C/O GENELUX CORPORATION, 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE CA 91361